PropertyValue
?:abstract
  • COVID-19 caused by SARS-COV2 infection can lead to multi-organ injuries and significant mortality in severe and critical patients, especially among those individuals with type 2 diabetes (T2D) as a comorbidity. While attenuated mortality was observed with aggressive glucose control, it was unclear whether therapeutic regiments including insulin treatment was beneficial for patients with COVID-19 and T2D. This retrospective study investigated 689 patients with COVID-19 and T2D from a cohort of 3,305 cases from Wuhan, China. Unexpectedly, we found that insulin treatment for patients with COVID-19 and T2D was associated with a significant increase in mortality [27.2% vs. 3.5%; adjusted HR, 5.38 (2.75-10.54)]. Further analysis showed that insulin treatment was associated with enhanced systemic inflammation and aggravated injuries of vital organs. Therefore, insulin treatment for patients with COVID-19 and T2D should be used with caution.
is ?:annotates of
?:creator
?:doi
?:doi
  • 10.1016/j.cmet.2020.11.014
?:journal
  • Cell_Metab
?:license
  • els-covid
?:pdf_json_files
  • document_parses/pdf_json/4f6ff3c77f64d85bdba55fdead6bcc13e57487da.json
?:pmcid
?:pmid
?:pmid
  • 33248471.0
?:publication_isRelatedTo_Disease
?:sha_id
?:source
  • Elsevier; Medline; PMC
?:title
  • Insulin treatment is associated with increased mortality in patients with COVID-19
?:type
?:year
  • 2020-11-23

Metadata

Anon_0  
expand all